

14 June 2021

ASX Code: MXC

LSE Code: MXC

## Issue of Shares & Resignation of Joint Company Secretary

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')** wishes to advise that it has recently issued the following fully paid ordinary shares in the Company:

1. 8,804,103 fully paid ordinary shares were issued to Cannvalate Pty Ltd on 14 June 2021 as part consideration for services rendered under a Service Contract.
2. 18,518 fully paid ordinary shares were issued on 1 June 2021 on the exercise of listed share options in the Company.

Additional information regarding the share issues above can be found in the Appendix 2A forms lodged with the ASX on 14 June 2021.

### Cleansing Notice:

Pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Corporations Act**"), the Company gives notice that in relation to the 8,804,103 ordinary shares issued to Cannvalate Pty Ltd, that:

- (a) the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; and
- (b) as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
- (c) as at the date of this notice, the Company has complied with section 674 of the Corporations Act as it applies to the Company; and
- (d) as at the date of this notice, there is no information to be disclosed which is "excluded information" as defined in subsection 708A(7) of the Corporations Act that is reasonable for investors and their professional advisors to find in a disclosure document.

### Resignation of Company Secretary:

With the recent appointment of Mr David Lim as Company Secretary announced on 09 June 2021, Ms Nadine Barry has resigned from the position of Company Secretary effective immediately.

Ms Barry will remain a member of the MGC team as Corporate Secretary. The Board would like to express its gratitude to Ms Barry for her contribution to the Company in regards to her role as Company Secretary.

—Ends—

**Authorised for issue by David Lim, Company Secretary, for further information, please contact:**

#### **PR/IR Advisors – Media & Capital Partners**

Rod Hinchcliffe (IR) +61 412 277 377  
Rod.Hinchcliffe@mcpartners.com.au

#### **UK Broker – Turner Pope**

Andy Thacker  
Andy.Thacker@TurnerPope.com  
Zoe Alexander +44 20 3657 0050  
Zoe.Alexander@TurnerPope.com

#### **MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
info@mgcpharma.com.au

#### **UK PR Advisors – Tavistock**

Charles Vivian +44 207 920 3150  
Charles.Vivian@tavistock.co.uk  
Tim Pearson +44 7983 118 502  
Tim.Pearson@tavistock.co.uk

## About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    